Brief: Camurus Announces FDA Approval Of Brixadi For Treatment Of Moderate To Severe Opioid Use Disorder
24/05/2023 04:19
May 23 (Reuters) - Camurus AB CAMX.ST :
* CAMURUS ANNOUNCES FDA APPROVAL OF BRIXADI™ FOR THE
TREATMENT OF
MODERATE TO SEVERE OPIOID USE DISORDER
* FDA APPROVAL OF BRIXADI TRIGGERS USD 35 MILLION IN
MILESTONE
REVENUE TO CAMURUS FROM BRAEBURN
* PRODUCT WILL BE MARKETED IN US BY CAMURUS' LICENSEE
BRAEBURN
Source text for Eikon: ID:nPn3rrng1a
Further company coverage: CAMX.ST
((Reuters.briefs@thomsonreuters.com;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat